Epigenetic control in Kaposi sarcoma-associated herpesvirus infection and associated disease.


Journal

Seminars in immunopathology
ISSN: 1863-2300
Titre abrégé: Semin Immunopathol
Pays: Germany
ID NLM: 101308769

Informations de publication

Date de publication:
04 2020
Historique:
received: 19 11 2019
accepted: 20 01 2020
pubmed: 29 3 2020
medline: 28 4 2021
entrez: 29 3 2020
Statut: ppublish

Résumé

Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several malignancies of endothelial and B-cell origin. The fact that latently infected tumor cells in these malignancies do not express classical viral oncogenes suggests that pathogenesis of KSHV-associated disease results from multistep processes that, in addition to constitutive viral gene expression, may require accumulation of cellular alterations. Heritable changes of the epigenome have emerged as an important co-factor that contributes to the pathogenesis of many non-viral cancers. Since KSHV encodes a number of factors that directly or indirectly manipulate host cell chromatin, it is an intriguing possibility that epigenetic reprogramming also contributes to the pathogenesis of KSHV-associated tumors. The fact that heritable histone modifications have also been shown to regulate viral gene expression programs in KSHV-infected tumor cells underlines the importance of epigenetic control during latency and tumorigenesis. We here review what is presently known about the role of epigenetic regulation of viral and host chromatin in KSHV infection and discuss how viral manipulation of these processes may contribute to the development of KSHV-associated disease.

Identifiants

pubmed: 32219477
doi: 10.1007/s00281-020-00787-z
pii: 10.1007/s00281-020-00787-z
pmc: PMC7174275
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

143-157

Références

Curr Opin Virol. 2013 Jun;3(3):266-75
pubmed: 23743127
Science. 1999 Apr 23;284(5414):641-4
pubmed: 10213686
Mod Pathol. 2002 Apr;15(4):434-40
pubmed: 11950918
J Virol. 2002 Jan;76(2):802-16
pubmed: 11752170
J Biol Chem. 2003 Dec 26;278(52):52437-45
pubmed: 14563855
J Virol. 2005 Jul;79(14):9301-5
pubmed: 15994824
Cell. 2012 Aug 31;150(5):922-33
pubmed: 22921915
Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Nat Cell Biol. 2013 Apr;15(4):373-84
pubmed: 23502314
PLoS Pathog. 2010 Jun 03;6(6):e1000935
pubmed: 20532208
J Virol. 2007 Dec;81(23):12836-45
pubmed: 17881434
RNA. 2006 May;12(5):733-50
pubmed: 16540699
Blood. 2003 Mar 1;101(5):1956-61
pubmed: 12406869
Ann Intern Med. 2015 Oct 6;163(7):507-18
pubmed: 26436616
J Virol. 2013 Jun;87(12):6782-93
pubmed: 23576503
Sci Adv. 2015 Aug 7;1(7):
pubmed: 26269799
J Virol. 1999 Jul;73(7):5722-30
pubmed: 10364323
Trends Microbiol. 2017 Aug;25(8):648-661
pubmed: 28259385
J Virol. 2007 Feb;81(4):1912-22
pubmed: 17121789
J Virol. 2014 Jul;88(13):7331-44
pubmed: 24741090
Nature. 1999 Dec 23-30;402(6764):889-94
pubmed: 10622254
Blood. 1995 Aug 15;86(4):1276-80
pubmed: 7632932
Nat Med. 2000 Oct;6(10):1121-7
pubmed: 11017143
Genes Dev. 2019 Aug 1;33(15-16):903-935
pubmed: 31123062
Nat Struct Mol Biol. 2017 Dec;24(12):1039-1047
pubmed: 29058710
Nat Methods. 2005 Apr;2(4):269-76
pubmed: 15782219
J Virol. 2002 Nov;76(22):11596-604
pubmed: 12388720
Blood. 2004 Nov 15;104(10):3349-54
pubmed: 15271792
Curr Opin Oncol. 2012 Sep;24(5):495-505
pubmed: 22729151
Mol Cell. 2014 Aug 7;55(3):347-60
pubmed: 24999238
J Virol. 1996 Nov;70(11):8218-23
pubmed: 8892957
J Virol. 2011 Oct;85(19):9877-86
pubmed: 21813606
J Virol. 2019 Feb 19;93(5):
pubmed: 30541837
J Virol. 2006 Sep;80(18):8909-19
pubmed: 16940503
Cell Host Microbe. 2017 Jul 12;22(1):61-73.e7
pubmed: 28704654
Blood. 2000 Oct 1;96(7):2537-42
pubmed: 11001908
J Gen Virol. 1999 Nov;80 ( Pt 11):2889-2900
pubmed: 10580050
Immunity. 2014 Jun 19;40(6):865-79
pubmed: 24856900
J Virol. 2006 Nov;80(21):10772-86
pubmed: 16928766
Curr Top Microbiol Immunol. 2007;312:137-56
pubmed: 17089796
Am J Dermatopathol. 1997 Aug;19(4):373-8
pubmed: 9261472
J Virol. 2010 Jun;84(11):5565-73
pubmed: 20219929
Int J Cancer. 2006 Sep 15;119(6):1262-7
pubmed: 16615115
J Virol. 1998 Oct;72(10):8309-15
pubmed: 9733875
PLoS Pathog. 2017 Sep 22;13(9):e1006639
pubmed: 28938025
Cancer. 2001 Dec 15;92(12):3076-84
pubmed: 11753987
J Virol. 2005 Nov;79(21):13618-29
pubmed: 16227282
J Virol. 2001 Jan;75(1):429-38
pubmed: 11119611
Blood. 1996 Oct 1;88(7):2648-54
pubmed: 8839859
Genes (Basel). 2015 Jun 23;6(2):353-71
pubmed: 26110314
Science. 1996 Dec 6;274(5293):1739-44
pubmed: 8939871
Curr Opin Virol. 2015 Oct;14:79-86
pubmed: 26372881
PLoS Pathog. 2013;9(12):e1003813
pubmed: 24367262
J Biol Chem. 2003 Dec 26;278(52):52406-11
pubmed: 14561765
PLoS Pathog. 2019 Dec 27;15(12):e1008221
pubmed: 31881074
mBio. 2018 Jan 16;9(1):
pubmed: 29339432
Curr Opin Virol. 2017 Oct;26:104-111
pubmed: 28802146
PLoS One. 2014 Mar 27;9(3):e93478
pubmed: 24675762
PLoS Pathog. 2014 Jul 17;10(7):e1004240
pubmed: 25033463
PLoS Pathog. 2012;8(5):e1002680
pubmed: 22589717
Nat Rev Mol Cell Biol. 2015 Nov;16(11):643-649
pubmed: 26420232
Curr Opin Virol. 2016 Oct;20:11-19
pubmed: 27518127
Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14554-9
pubmed: 16983096
J Virol. 2004 Nov;78(22):12566-75
pubmed: 15507644
PLoS Pathog. 2018 Sep 13;14(9):e1007253
pubmed: 30212568
Nat Rev Dis Primers. 2019 Jan 31;5(1):9
pubmed: 30705286
J Virol. 2013 May;87(10):5540-53
pubmed: 23468496
Am J Pathol. 2000 Mar;156(3):743-9
pubmed: 10702388
PLoS Pathog. 2014 Jul 17;10(7):e1004274
pubmed: 25033267
Int J Biochem Cell Biol. 2015 Oct;67:177-87
pubmed: 25982201
J Virol. 2004 Apr;78(7):3601-20
pubmed: 15016882
J Clin Oncol. 2005 Aug 1;23(22):5224-8
pubmed: 16051964
Nature. 2007 Dec 13;450(7172):1096-9
pubmed: 18075594
J Virol. 2003 Feb;77(4):2779-83
pubmed: 12552022
Oncogene. 1999 Oct 14;18(42):5738-46
pubmed: 10523854
Cell Host Microbe. 2013 Apr 17;13(4):429-40
pubmed: 23601105
J Virol. 2015 May;89(10):5536-56
pubmed: 25740990
PLoS One. 2012;7(11):e49435
pubmed: 23185331
N Engl J Med. 1995 May 4;332(18):1186-91
pubmed: 7700311
Sci Rep. 2016 Sep 07;6:32633
pubmed: 27599637
Clin Infect Dis. 2004 Dec 15;39(12):1852-5
pubmed: 15578411
J Virol. 2002 Dec;76(24):12574-83
pubmed: 12438583
J Biol Chem. 2003 Feb 28;278(9):7397-405
pubmed: 12486118
Trends Cell Biol. 2014 Nov;24(11):664-74
pubmed: 25242115
J Virol. 2002 Oct;76(20):10320-31
pubmed: 12239308
Virology. 1999 Nov 25;264(2):254-64
pubmed: 10562490
Cancer Res. 2006 Apr 1;66(7):3658-66
pubmed: 16585191
Clin Infect Dis. 2016 Mar 15;62(6):730-738
pubmed: 26658701
Mol Cancer. 2007 Apr 13;6:28
pubmed: 17433107
Curr Opin Virol. 2015 Oct;14:116-28
pubmed: 26431609
J Clin Invest. 2004 Jan;113(1):124-36
pubmed: 14702116
Cancer Res. 2012 Jul 15;72(14):3582-92
pubmed: 22593192
J Virol. 2011 Dec;85(24):13290-7
pubmed: 21957289
Nat Med. 2003 Mar;9(3):300-6
pubmed: 12592400
J Virol. 2010 Mar;84(6):2697-706
pubmed: 20071580
PLoS Pathog. 2019 Oct 31;15(10):e1007838
pubmed: 31671162
Sci Adv. 2015 Dec 04;1(11):e1500737
pubmed: 26665172
J Virol. 1997 Jun;71(6):4193-8
pubmed: 9151805
Nat Struct Mol Biol. 2013 Oct;20(10):1147-55
pubmed: 24096405
Cancer Res. 2018 Jan 1;78(1):230-245
pubmed: 29066510
Cell. 2017 Sep 21;171(1):34-57
pubmed: 28938122
Clin Infect Dis. 2010 Aug 1;51(3):350-8
pubmed: 20583924
Cell. 2014 Jun 5;157(6):1445-59
pubmed: 24856970
Nat Commun. 2019 Apr 29;10(1):1931
pubmed: 31036804
J Virol. 2012 May;86(10):5752-62
pubmed: 22419807
Anticancer Res. 1994 May-Jun;14(3A):921-6
pubmed: 8074494
EMBO Rep. 2015 Dec;16(12):1609-19
pubmed: 26553936
Nature. 2017 Sep 14;549(7671):287-291
pubmed: 28869966
J Exp Med. 2004 Apr 5;199(7):993-1003
pubmed: 15067035
Nat Med. 1996 Mar;2(3):342-6
pubmed: 8612236
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5
pubmed: 15800047
Virology. 2011 Mar 15;411(2):325-43
pubmed: 21277611
Cancer. 2007 Aug 25;111(4):224-33
pubmed: 17554754
Biol Chem. 2017 Jul 26;398(8):857-870
pubmed: 28455950
Virology. 2000 Apr 10;269(2):335-44
pubmed: 10753712
Elife. 2012 Dec 18;1:e00205
pubmed: 23256043
Blood. 2008 Jan 1;111(1):320-7
pubmed: 17890449
Blood. 1995 Oct 1;86(7):2708-14
pubmed: 7670109
PLoS Pathog. 2019 Jan 30;15(1):e1007578
pubmed: 30699189
Virology. 2006 May 10;348(2):309-27
pubmed: 16546233
PLoS Pathog. 2017 Jan 20;13(1):e1006100
pubmed: 28107481
Nat Genet. 2018 Jul;50(7):1002-1010
pubmed: 29808031
Cell Stem Cell. 2014 Jun 5;14(6):735-51
pubmed: 24905164
Virology. 1994 Aug 15;203(1):153-7
pubmed: 8030271
J Virol. 2004 Jul;78(14):7299-310
pubmed: 15220403
PLoS Pathog. 2016 Sep 08;12(9):e1005878
pubmed: 27606464
J Virol. 2002 Nov;76(22):11677-87
pubmed: 12388727
PLoS Pathog. 2010 Jul 22;6(7):e1001013
pubmed: 20661424
J Virol. 2014 Jun;88(12):6762-77
pubmed: 24696474
J Virol. 1997 Mar;71(3):1984-91
pubmed: 9032330
Curr Opin Hematol. 2014 Jul;21(4):358-68
pubmed: 24886824
Nature. 1996 Aug 1;382(6590):410
pubmed: 8684480
PLoS Pathog. 2014 Jul 10;10(7):e1004154
pubmed: 25010730
J Virol. 2010 Oct;84(19):9718-32
pubmed: 20660191
IARC Monogr Eval Carcinog Risks Hum. 2014;104:9-350
pubmed: 26173303
Philos Trans R Soc Lond B Biol Sci. 2013 Jan 5;368(1609):20110332
pubmed: 23166395
Nat Commun. 2017 Jun 26;8(1):36
pubmed: 28652613
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
Mol Cell. 2013 Mar 28;49(6):1134-46
pubmed: 23395003
Blood. 2008 May 1;111(9):4731-40
pubmed: 18199825
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879
PLoS Pathog. 2013;9(10):e1003640
pubmed: 24146614
Science. 2006 Feb 10;311(5762):856-61
pubmed: 16469929

Auteurs

Jacqueline Fröhlich (J)

Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany.

Adam Grundhoff (A)

Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany. adam.grundhoff@leibniz-hpi.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH